# US 11,993,636 B2 · Antigenic OspA polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,636 B2
- Document ID: US11993636B2
- Status: Granted
- Kind: B2
- Application number: 17/061,155
- Filed: 2020-10-01
- Published: 2021-01-21
- Granted: 2024-05-28
- Earliest claimed: 2018-04-03
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Gary J. Nabel; Chih-Jen Wei; Heather Kamp; Ronnie Wei; Kurt Swanson
- Web page: https://patentgrep.com/patent/US11993636B2

## CPC

- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- C07K 14/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- A61P 31/04: Antibacterial agents
- C07K 14/195: from bacteria
- C07K 14/205: from Campylobacter (G)
- C12N 9/1085: {transferring alkyl or aryl groups other than methyl groups (2.5)}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/6031: {Proteins}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

## Claims

### Claim 1

A composition comprising (a) an antigenic outer surface protein A (OspA) serotype 1 polypeptide of Borrelia and (b) a ferritin protein, wherein the OspA serotype 1 polypeptide of Borrelia does not comprise the sequence of SEQ ID NO: 77, wherein the OspA serotype 1 polypeptide of Borrelia comprises a sequence with at least 90% identity to the sequence of any one of SEQ ID NOS: 1, 3, 4, 53, or 94-102, and wherein the ferritin protein comprises a bullfrog linker that has the sequence of SEQ ID NO: 217, and wherein the ferritin protein comprises a sequence having at least 90% identity to SEQ ID NO: 90.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ferritin protein comprises a mutation replacing a surface-exposed amino acid with a cysteine.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the ferritin protein comprises one or more of El 2C, S26C, S72C, A75C, K79C, S100C, and S111C mutations of H. pylori ferritin or one or more corresponding mutations in a non-H. pylori ferritin as determined by pairwise or structural alignment.

### Claim 4 (depends on 1)

The composition of claim 1, comprising one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid, wherein the surface-exposed amino acid is a cysteine resulting from a mutation.

### Claim 5 (depends on 1)

A ferritin particle comprising the composition of claim 1.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.